FPC
AVDL

Falcon Point Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Falcon Point Capital’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-661,490
Closed -$6.28M – 122
2017
Q3 		$6.28M Sell
661,490
-193,611
-23% -$1.85M 0.91% 45
2017
Q2 		$9.43M Sell
855,101
-26,142
-3% -$262K 1.27% 39
2017
Q1 		$8.53M Sell
881,243
-6,396
-0.7% -$64K 1.14% 40
2016
Q4 		$9.22M Buy
887,639
+56,967
+7% +$626K 1.24% 38
2016
Q3 		$8.97M Sell
830,672
-185,169
-18% -$2.42M 1.37% 38
2016
Q2 		$10.9M Buy
1,015,841
+10,973
+1% +$117K 1.88% 23
2016
Q1 		$11.1M Buy
1,004,868
+269,603
+37% +$2.68M 1.91% 22
2015
Q4 		$8.98M Buy
735,265
+342,445
+87% +$5.34M 1.94% 23
2015
Q3 		$6.41M Buy
392,820
+10,057
+3% +$222K 2.29% 8
2015
Q2 		$8.11M Buy
382,763
+279,119
+269% +$5M 2.74% 4
2015
Q1 		$1.86M Buy
+103,644
New +$1.62M 1.45% 20

Other funds holding AVDL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Falcon Point Capital's AVDL Position: Q4 2017 in Review

Falcon Point Capital sold out of Avadel Pharmaceuticals (AVDL) in Q4 2017, closing a stake of 661,490 shares — an estimated $6.28M sold.

Falcon Point Capital first reported a position in AVDL in Q1 2015 and held it in 11 quarters. The position peaked at $11.1M in Q1 2016. 83 funds tracked by Wall St. Rank hold AVDL as of Q4 2017.

  • Falcon Point Capital reported no remaining Avadel Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Falcon Point Capital sold 661,490 Avadel Pharmaceuticals shares in Q4 2017, an estimated $6.28M.
  • Falcon Point Capital first reported a position in Avadel Pharmaceuticals in Q1 2015 and held it in 11 quarters.
  • Falcon Point Capital's Avadel Pharmaceuticals position peaked at $11.1M in Q1 2016.
  • 83 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2017.

Based on Falcon Point Capital's 13F filing for Q4 2017, filed 8 Feb 2018.